日本の2型糖尿病患者における経口セマグルチドの作用機序を検証する研究（地域臨床実践の一環として）

基本情報

NCT ID

NCT04878393

ステータス

完了

試験のフェーズ

-

試験タイプ

観察

目標被験者数

650

治験依頼者名

Novo Nordisk A/S

概要

The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels, and to get side-effects information. Participants will get Rybelsus® as prescribed to them by the study doctor. The study will last for about 8-10 months. Participants will be asked to complete a questionnaire about how they take their Rybelsus® tablets. Participants will complete this questionnaire during their normally scheduled visit with the study doctor.

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)